|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash ($163.1 and $37.3 related to variable interest entities (VIEs)) | ||||||||||||||||||||
| Mortgage servicing rights (MSRs), at fair value | ||||||||||||||||||||
| Advances, net ($277.2 and $364.5 related to VIEs) | ||||||||||||||||||||
| Loans held for sale, at fair value ($2,397.5 and $1,199.8 related to VIEs) | ||||||||||||||||||||
| Reverse loans held for sale pooled into Home Equity Conversion Mortgage Backed Securities (HMBS), at fair value | ||||||||||||||||||||
| Loans held for investment, at fair value | ||||||||||||||||||||
| Reverse loans held for sale pooled into Home Equity Conversion Mortgage-Backed Securities (HMBS), at fair value | ||||||||||||||||||||
| Reverse loans held for investment pooled into HMBS, at fair value | ||||||||||||||||||||
| Receivables, net ($80.2 and $64.2 related to VIEs) | ||||||||||||||||||||
| Investment in equity method investee | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Other assets ($41.9 and $28.4 carried at fair value) ($164.6 and $83.4 related to VIEs) | ||||||||||||||||||||
| Loan Repurchase Asset | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| HMBS-related borrowings, at fair value | ||||||||||||||||||||
| MSR related financing liabilities, at fair value | ||||||||||||||||||||
| Advance match funded liabilities ($254.7 and $341.4 related to VIEs) | ||||||||||||||||||||
| Mortgage warehouse facilities | ||||||||||||||||||||
| Reverse mortgage securitization notes, net (related to VIE) | ||||||||||||||||||||
| MSR financing facilities, net | ||||||||||||||||||||
| Senior notes, net | ||||||||||||||||||||
| Other liabilities ($11.7 and $10.2 carried at fair value) | ||||||||||||||||||||
| Contingent loan repurchase liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Series B Preferred stock, $0.01 par value and $25.00 liquidation preference value; 2,400,000 shares authorized; 2,111,786 and 2,111,786 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Common stock, $0.01 par value; 13,333,333 shares authorized; 8,406,047 and 8,521,636 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net of income taxes | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities, mezzanine equity and stockholders’ equity | ||||||||||||||||||||
Loading...
